The joint diabetic-renal clinic in clinical practice: 10 years of data from a District General Hospital

QJM: An International Journal of Medicine

Volumn 99, Issue 3, 2006, Pages 153-160

  Jayapaul, M K ^a,b   Messersmith, R ^a   Bennett Jones, D N ^a   Mead, P A ^a   Large, D M ^a  

^a CUMBERLAND INFIRMARY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC ANGIOPATHY; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; GENERAL HOSPITAL; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

EID: 33645289387     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcl016     Document Type: Review

References (41)

1. U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.
2. Ansell D, Feest T. The Second Annual Report, The UK Renal Registry. Bristol, 1999.
3. Finne P, Reunanen A, Stenman S, Groop PH, Gronhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294:1782-7.
4. American Association. Position statement: Diabetic Nephropathy. Diabetes Care 2004; 27(Suppl. 1):S79-83.
5. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed) 1982; 285:685-8.
6. Parving HH, Hommel E. High blood pressure is a major factor in progression of diabetic nephropathy. J Diabet Complications 1988; 2:92-5.
7. Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38:604-9.
8. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 2001; 59:260-9.
9. The effect of intensive treatment of diabetes on the development, & progression of long-term complications in insulin-dependent diabetes mellitus The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977-86.
10. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-53.
11. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 1999; 319:24-5.
12. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-8.
13. Chuahirun T, Simoni J, Hudson C, Seipel T, Khanna A, Harrist RB, et al. Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am J Med Sci 2004; 327:57-67.
14. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis. Ann Intern Med 1996; 124:627-32.
15. Diabetes care and research in Europe: The Saint Vincent declaration. Diabet Med 1990; 7:360.
16. SIGN. Management of diabetes. Report no. 55. Scottish Intercollegiate Guidelines Network, 2001.
17. NICE. Management of type 2 diabetes - renal disease, prevention and early management. Inherited Clinical guideline F. London, National Institute for Clinical Excellence, 2002.
18. Bergstrom J, Alvestrand A, Bucht H, Gutierrez A. Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrol 1986; 25:1-6.
19. Liew BS, Perry C, Boulton-Jones JM, Simpson K, Paterson K. Diabetic nephropathy: An observational study on patients attending a joint diabetes renal clinic. Q J Med 1997; 90:353-8.
20. Joss N, Paterson KR, Deighan CJ, Simpson K, Boulton-Jones JM. Diabetic nephropathy: How effective is treatment in clinical practice? Q J Med 2002; 95:41-9.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
22. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet 1999; 353:617-22.
23. Feest TG, Dunn EJ, Burton CJ. Can intensive treatment alter the progress of established diabetic nephropathy to end-stage renal failure? Q J Med 1999; 92:275-82.
24. Dunn EJ, Burton CJ, Feest TG. The care of patients with diabetic nephropathy: Audit, feedback, and improvement. Q J Med 1999; 92:443-9.
25. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317:703-13.
26. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-60.
27. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, et al. Effects of Blood Pressure Level on Progression of Diabetic Nephropathy: Results From the RENAAL Study. Arch Intern Med 2003; 163:1555-65.
28. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind cross-over trial. Diabetes Care 2003; 26:2268-74.
29. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000; 321:1440-4.
30. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001; 134:629-36.
31. Ahuja TS, Freeman D Jr, Mahnken JD, Agraharkar M, Siddiqui M, Memon A. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 2000; 20:268-72.
32. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-70.
33. Rolin HA 3rd, Hall PM, Wei R. Inaccuracy of estimated creatinine clearance for prediction of iothalamate glomerular filtration rate. Am J Kidney Dis 1984; 4:48-54.
34. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clip Res Ed) 1987; 294:1443-7.
35. Adebonojo SA, Bowser AN, Moritz DM, Corcoran PC. Impact of Revised Stage Classification of Lung Cancer on Survival: A Military Experience. Chest 1999; 115:1507-13.
36. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. N Engl J Med 1998; 339:229-34.
37. Hall WD. Abnormalities of kidney function as a cause and a consequence of cardiovascular disease. Am J Med Sci 1999; 317:176-82.
38. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant 1998; 13:2281-7.
39. Amadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 1996; 56:41-6.
40. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(Suppl. 3):S112-19.
41. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34:795-808.